Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 140Terminated 24Active not recruiting 13Withdrawn 10Unknown 7Recruiting 7Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Specimen Handling 8Magnetic Resonance Spectroscopy 7Biopsy 5Nivolumab 4Capecitabine 4Vincristine 3Radiosurgery 3Paclitaxel 3Irinotecan 3Fluorouracil 3Everolimus 3Docetaxel 3Dexamethasone 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3trifluridine tipiracil drug combination 2spartalizumab 2pembrolizumab 2lenvatinib 2daratumumab 2Taxes 2Radiation 2Prednisone 2Pemetrexed 2Oxaliplatin 2Mitoxantrone 2Leucovorin 2Injections 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Suspended × sargramostim × Clear all
NCT00278122 2013-12-10

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

University of Virginia

Phase 2 Suspended
42 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡